Compare EOT & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOT | QTRX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.2M | 306.0M |
| IPO Year | 2009 | 2017 |
| Metric | EOT | QTRX |
|---|---|---|
| Price | $17.07 | $3.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 26.7K | ★ 911.1K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,632,000.00 |
| Revenue This Year | N/A | $25.49 |
| Revenue Next Year | N/A | $10.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $15.89 | $2.95 |
| 52 Week High | $18.00 | $8.77 |
| Indicator | EOT | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 42.24 |
| Support Level | $16.53 | $3.30 |
| Resistance Level | $17.26 | $3.81 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 40.82 | 46.41 |
Eaton Vance National Municipal Opportunities Trust is a diversified, closed-end management investment company. The company's investment objective is to provide current income exempt from regular federal income tax and to achieve capital appreciation. The company invests a majority of its assets in debt obligations issued by or on behalf of states, territories, and possessions of the United States, including the District of Columbia, and their political subdivisions, agencies, or instrumentalities, the interest on which is exempt from regular federal income tax.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.